ZYL 2525Alternative Names: ZYL2525
Latest Information Update: 27 Nov 2015
At a glance
- Originator Zylera Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Unspecified
Most Recent Events
- 27 Nov 2015 Phase III development is ongoing in USA